CymaBay Therapeutics Inc (USD)
CBAY
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 1.64 | 1.73 |
| 52-Wk Range | 1.29 | 14.00 |
| Last Close | 1.66 |
| Mkt Cap (m) | 114.04 |
| Dividend yield | - |
| ISIN | US23257D1037 |
| Volume | 1,364,248 |
| Exchange Venue | NAS |
Company Profile
CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.
Key Information
| Price/Earning | - |
| Price/Book | 0.54 |
| Price/Sales | - |
| P/CF | - |
| Rev Growth (3 year avg) | 0.00 |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | -56.82 |
| Debt/Equity | - |
Legal Documents
Prospectus
| en 06/03/2019 |
Annual Report
| en 31/12/2018 |
Financials
Income Statement
| USD | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Revenue (m) | 10 | |||||
| Operating Income (m) | -9 | -24 | -26 | -26 | -21 | -73 |
| Net Income (m) | -10 | -32 | -16 | -27 | -28 | -73 |
| Basic EPS | 17.35 | -2.65 | -0.82 | -1.14 | -0.79 | -1.25 |
| Avg. Diluted Shares Outstanding (m) | 14 | 12 | 19 | 23 | 35 | 58 |
Balance Sheet
| USD | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Current Assets (m) | 32 | 37 | 43 | 19 | 104 | 182 |
| Non Current Assets (m) | 1 | 1 | 5 | |||
| Total Assets (m) | 33 | 37 | 43 | 19 | 104 | 187 |
| Current Liabilities (m) | 9 | 20 | 6 | 9 | 16 | 14 |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 19 | 14 | 28 | 4 | 85 | 170 |
Cash Flows
| USD | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Operating Cash Flows (m) | -8 | -21 | -23 | -23 | -20 | -55 |
| Capital Expenditure (m) | - | - | -1 |
Figures are quoted in USD unless stated otherwise
0.04 (2.41%)
$
1.70
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.